| P2093 | author name string | Amine Kamen | |
| | Alexandre Audy | |
| | Bruno Gaillet | |
| | Marc-André Robert | |
| | Parminder S Chahal | |
| | Rénald Gilbert | |
| P2860 | cites work | Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. | Q42408230 |
| | Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing. | Q42408255 |
| | Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. | Q43567043 |
| | Development of formulations that enhance physical stability of viral vectors for gene therapy. | Q43747167 |
| | Production of recombinant adeno-associated viral vectors using a baculovirus/insect cell suspension culture system: from shake flasks to a 20-L bioreactor | Q44295404 |
| | Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography | Q45408693 |
| | Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression | Q45419907 |
| | Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. | Q45730550 |
| | Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography | Q45731650 |
| | Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield | Q45747699 |
| | Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system | Q45747815 |
| | Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses | Q45749766 |
| | Novel tools for production and purification of recombinant adenoassociated virus vectors | Q45752072 |
| | Purified influenza virus vaccine. A study of viral reactivity and antigenicity | Q45810527 |
| | High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency | Q45855465 |
| | Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation | Q46553714 |
| | Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors | Q24529153 |
| | Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity | Q24529161 |
| | Evidence for packaging of rep-cap sequences into adeno-associated virus (AAV) type 2 capsids in the absence of inverted terminal repeats: a model for generation of rep-positive AAV particles | Q24540530 |
| | Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification | Q24606577 |
| | Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies | Q24630417 |
| | Manufacturing of recombinant adeno-associated viral vectors for clinical trials | Q26750799 |
| | Characteristics of a human cell line transformed by DNA from human adenovirus type 5 | Q29547863 |
| | Evaluation of a Serum-free Medium for the Production of rAAV-2 using HeLa Derived Producer Cells | Q30462040 |
| | Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years | Q30537764 |
| | Comparative analysis of adeno-associated virus capsid stability and dynamics | Q30557598 |
| | Scalable downstream strategies for purification of recombinant adeno- associated virus vectors in light of the properties | Q33555259 |
| | Characterization of genome integrity for oversized recombinant AAV vector | Q33576852 |
| | Quantification of AAV particle titers by infrared fluorescence scanning of coomassie-stained sodium dodecyl sulfate-polyacrylamide gels. | Q33586275 |
| | Induction of immune tolerance to FIX by intramuscular AAV gene transfer is independent of the activation status of dendritic cells | Q33608746 |
| | A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells | Q33713203 |
| | Effect of genome size on AAV vector packaging | Q33730405 |
| | The interaction of heparin sulfate and adeno-associated virus 2. | Q33895117 |
| | Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material | Q34211507 |
| | Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo | Q34277742 |
| | A pseudo-plaque method for infectious particle assay and clonal isolation of adeno-associated virus | Q34311511 |
| | Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection | Q34770058 |
| | Self-complementary AAV vectors; advances and applications | Q34804660 |
| | Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial | Q34843808 |
| | Systemic elimination of de novo capsid protein synthesis from replication-competent AAV contamination in the liver | Q34843835 |
| | Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6 | Q35024289 |
| | Immune responses to adeno-associated virus and its recombinant vectors | Q35131229 |
| | Reproducible high yields of recombinant adeno-associated virus produced using invertebrate cells in 0.02- to 200-liter cultures | Q35174927 |
| | Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results | Q35496285 |
| | Adenovirus-associated virus vector-mediated gene transfer in hemophilia B | Q35691659 |
| | Scalable purification of adeno-associated virus serotype 1 (AAV1) and AAV8 vectors, using dual ion-exchange adsorptive membranes. | Q39836878 |
| | Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells | Q39856071 |
| | A sensitive cell-based assay to measure the doxycycline concentration in biological samples. | Q39885872 |
| | An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes | Q39928784 |
| | Biodistribution and safety profile of recombinant adeno-associated virus serotype 6 vectors following intravenous delivery. | Q40091715 |
| | High-titer, serum-free production of adeno-associated virus vectors by polyethyleneimine-mediated plasmid transfection in mammalian suspension cells | Q40106097 |
| | Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells | Q40139433 |
| | A simplified purification protocol for recombinant adeno-associated virus vectors. | Q40286092 |
| | Endotoxin detection--from limulus amebocyte lysate to recombinant factor C. | Q40354962 |
| | Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. | Q40397170 |
| | Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors | Q40493311 |
| | Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events | Q40527772 |
| | Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. | Q40642180 |
| | Quantification of adeno-associated virus particles and empty capsids by optical density measurement | Q40672137 |
| | Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors | Q40692830 |
| | Resolving Adeno-Associated Viral Particle Diversity With Charge Detection Mass Spectrometry. | Q40697697 |
| | Development and Optimization of AAV hFIX Particles by Transient Transfection in an iCELLis(®) Fixed-Bed Bioreactor. | Q40733859 |
| | A single-step affinity column for purification of serotype-5 based adeno-associated viral vectors. | Q40775922 |
| | A helper virus-free packaging system for recombinant adeno-associated virus vectors | Q40916579 |
| | High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. | Q40933793 |
| | High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus | Q40992577 |
| | Adeno-associated virus site-specific integration and AAVS1 disruption | Q41039070 |
| | Cell lines for the production of recombinant adeno-associated virus | Q41286219 |
| | Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release | Q41443741 |
| | Simple downstream process based on detergent treatment improves yield and in vivo transduction efficacy of adeno-associated virus vectors | Q41551945 |
| | Evidence for pH-dependent protease activity in the adeno-associated virus capsid | Q41578092 |
| | Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids | Q41630679 |
| | Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. | Q41746617 |
| | Proteomics analysis of co-purifying cellular proteins associated with rAAV vectors | Q41778815 |
| | A novel and rapid method to determine doxycycline in human plasma by liquid chromatography tandem mass spectrometry | Q41901273 |
| | Primary recovery and chromatographic purification of adeno-associated virus type 2 produced by baculovirus/insect cell system | Q42035778 |
| | Enhanced growth of Sf-9 cells to a maximum density of 5.2 x 10(7) cells per mL and production of beta-galactosidase at high cell density by fed batch culture | Q42056898 |
| | Development of a rapid, robust, and universal picogreen-based method to titer adeno-associated vectors | Q42173116 |
| | Generation and characterization of adeno-associated virus producer cell lines for research and preclinical vector production | Q42284310 |
| | AAV empty capsids: for better or for worse? | Q42369433 |
| | Recombinant adeno-associated viral vector production and purification. | Q35819157 |
| | Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies | Q36142496 |
| | Current issues in adeno-associated viral vector production | Q36288924 |
| | Systemic errors in quantitative polymerase chain reaction titration of self-complementary adeno-associated viral vectors and improved alternative methods | Q36807045 |
| | Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectors | Q36867801 |
| | Advanced Characterization of DNA Molecules in rAAV Vector Preparations by Single-stranded Virus Next-generation Sequencing | Q36939744 |
| | CpG-depleted adeno-associated virus vectors evade immune detection. | Q36966955 |
| | Immune responses to AAV vectors: overcoming barriers to successful gene therapy | Q36983740 |
| | Large-Scale Production of Adeno-Associated Viral Vector Serotype-9 Carrying the Human Survival Motor Neuron Gene | Q37101783 |
| | Manufacturing and characterizing AAV-based vectors for use in clinical studies | Q37140657 |
| | AAV2/8 vectors purified from culture medium with a simple and rapid protocol transduce murine liver, muscle, and retina efficiently | Q37406911 |
| | Transient transfection methods for clinical adeno-associated viral vector production | Q37479802 |
| | Manufacturing recombinant adeno-associated viral vectors from producer cell clones | Q37619514 |
| | Mycoplasma testing of cell substrates and biologics: Review of alternative non-microbiological techniques | Q37828246 |
| | Adeno-associated virus biology | Q37950280 |
| | Basic biology of adeno-associated virus (AAV) vectors used in gene therapy | Q38192720 |
| | Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside | Q38195598 |
| | Rep/Cap gene amplification and high-yield production of AAV in an A549 cell line expressing Rep/Cap. | Q38289588 |
| | Manufacturing of recombinant adeno-associated viral vectors: new technologies are welcome | Q38505122 |
| | Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector | Q38830211 |
| | Analytical Ultracentrifugation as an Approach to Characterize Recombinant Adeno-Associated Viral Vectors | Q38831854 |
| | Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR. | Q38831889 |
| | Rational plasmid design and bioprocess optimization to enhance recombinant adeno-associated virus (AAV) productivity in mammalian cells | Q38973135 |
| | Stability and compatibility of recombinant adeno-associated virus under conditions commonly encountered in human gene therapy trials | Q39024016 |
| | Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery | Q39062624 |
| | Analysis of particle content of recombinant adeno-associated virus serotype 8 vectors by ion-exchange chromatography. | Q39407680 |
| | Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses | Q39501488 |
| | Vector characterization methods for quality control testing of recombinant adeno-associated viruses | Q39540674 |
| | A versatile adeno-associated virus vector producer cell line method for scalable vector production of different serotypes | Q39615423 |
| | Clearance and characterization of residual HSV DNA in recombinant adeno-associated virus produced by an HSV complementation system | Q39674124 |
| | Feasibility of generating adeno-associated virus packaging cell lines containing inducible adenovirus helper genes | Q39682511 |
| | A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines | Q39685433 |
| | Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity | Q39686097 |
| | A scalable method for the production of high-titer and high-quality adeno-associated type 9 vectors using the HSV platform | Q39737661 |
| P433 | issue | 3 | |
| P577 | publication date | 2017-02-08 | |
| P1433 | published in | Biotechnology Journal | Q15716480 |
| P1476 | title | Manufacturing of recombinant adeno-associated viruses using mammalian expression platforms | |
| P478 | volume | 12 | |